Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

Table 3 Treatment effects in various subsets

Subset	RX Arm	# Pts	Median OS Months	3-year OS	P value
Measurable	DCV	8	17.6	38%	0.122
Measurable	TCV	9	9.0	11%
Not Measurable	DCV	10	44.6	80%	0.332
Not Measurable	TCV	15	32.2	33%
Not NED	DCV	14	25.2	50%	0.011
Not NED	TCV	13	9.9	8%
NED	DCV	4	53.0	75%	0.561
NED	TCV	11	33.7	40%
High LDH St 4	DCV	6	17.6	17%	0.010
High LDH St 4	TCV	3	1.1	0%
WNL LDH	DCV	11	53.0	82%	0.079
WNL LDH	TCV	20	21.1	25%
KPS =100	DCV	9	44.6	67%	0.810
KPS =100	TCV	12	32.2	33%
KPS < 100	DCV	9	38.6	56%	0.303
KPS < 100	TCV	12	9.0	17%
Stage 4	DCV	16	38.6	56%	0.292
Stage 4	TCV	17	16.9	24%
Stage 3	DCV	2	> 60	100%	0.141
Stage 3	TCV	7	32.2	29%

RX arm treatment arm, Pts patients, OS overall survival, DCV dendritic cell vaccine, TCV = tumor cell vaccine, NED no evidence of disease, LDH serum lactate dehydrogenase, St 4 stage 4, KPS Karnofsky Performance Status